Miach Orthopaedics Expands Senior Executive Team

WESTBOROUGH, Mass.--April 17, 2018)--Miach Orthopaedics, Inc., a privately held company dedicated to developing bio-engineered surgical implants for connective tissue repair, today announced two additions to its senior executive team to oversee quality systems and clinical trials for the Bridge-Enhanced® ACL Repair (BEAR®) implant for anterior cruciate ligament (ACL) repair. Michael O’Hara joined as vice president of quality assurance and Rita Paparazzo, MBA, as senior director of clinical operations.

“We are building a team of hard-working, collaborative, innovative employees at Miach,” said Martha Shadan, president and CEO. “Mike and Rita are results-driven individuals with substantial experience in their respective areas.”

O’Hara brings extensive expertise in compliance, product quality, quality systems and customer satisfaction, having served in quality assurance roles at TransMedics, ABIOMED, Medtronic and Baxter. While at TransMedics he led premarket approval (PMA) submissions for two products and oversaw U.S. Food and Drug Administration manufacturing inspections. At Miach, O’Hara is responsible for developing, implementing and managing the company’s quality function and quality management systems, including overseeing manufacturing and ensuring compliance within applicable regulations and standards.

Paparazzo is an experienced clinical trials research and clinical operations professional with a background in orthopedics. Through her roles at Boston Biomedical Associates and Inverness Medical/Biosite Inc., she managed multiple clinical trials, including an investigational device exemption trial from its inception through to the product’s PMA. At Miach, Paparazzo is responsible for the strategic and tactical execution of the company’s clinical trials for the BEAR implant.

About ACL Injuries and the BEAR® Implant

Every year, approximately 200,000 anterior cruciate ligament (ACL) injuries occur in the U.S. Without treatment, the ACL does not heal, resulting in ACL reconstruction surgery being one of the most common orthopaedic procedures in the U.S. Miach Orthopaedics’ new Bridge-Enhanced® ACL Repair (BEAR®) technology is a proprietary bio-engineered bridging scaffold used to facilitate healing of the torn ACL. It is hoped this new technology will restore more normal anatomy and function of the knee, and thus enable a higher percentage of patients to get back to activities they enjoy. The BEAR implant is an investigational device and is only available in FDA-approved clinical trials.

About Miach Orthopaedics, Inc.

Miach Orthopaedics, Inc. is a privately held company located in Westborough, Massachusetts, dedicated to developing bio-engineered surgical implants for connective tissue repair. The company’s initial focus is on the Bridge-Enhanced® ACL Repair (BEAR®) technology as a viable alternative to conventional ACL reconstruction for patients who have sustained an ACL injury. The BEAR technology was pioneered by Martha Murray, M.D., at the Boston Children’s Hospital Department of Orthopaedic Surgery with initial research funding provided by the NFL Players Association, Boston Children’s Hospital and the National Institutes of Health. For more information on Miach Orthopaedics and its products, visit www.miachortho.com and follow the company on Twitter and LinkedIn.